News

Advaxis has received approval from the New England Institutional Review Board (IRB) to enroll the first patient in a phase II clinical trial of cervical dysplasia (cervical intraepithelial

Shire has received approval through the European Mutual Recognition Procedure for an extension to the current indication for Fosrenol (lanthanum carbonate). Reportedly, the extension is to make the

The product previously referred to on a pre-commercial basis as the Unilife Ready-to-Fill Syringe (or Unilife Prefilled Syringe) will henceforth be marketed and referred to as the Unifill

Infor-Med has announced the beta release of Praxis Version 5 featuring Datum, a tool that allows physicians to use free text to create, store, and share discrete clinical

GTX Corp and MNX have entered into an exclusive product test agreement to develop a proprietary GPS enabled transport container. Over the following 2 quarters the companies will

ZymoGenetics has initiated phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection (EMERGE study). The first patient

Carefx has announced that Boston Medical Center (BMC) has deployed the Fusionfx Immunization Management portal designed to enter and track H1N1 vaccination administration history and support broad, community-wide

GlaxoSmithKline (GSK) and Genmab have received accelerated approval for Arzerra (ofatumumab) from the FDA for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine

The Food and Drug Administration (FDA) has withdrawn a notice of eligibility and call-for-data for safety and effectiveness regarding Saccharomyces boulardii (S. boulardii). In the original notice published